ESPR

Esperion Therapeutics, Inc. NASDAQ

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · esperion.com

$3.12

Pre-mkt $3.11 -0.32%

Mkt Cap $648.7M

52w Low $0.69 69.6% of range 52w High $4.18

50d MA $2.56 200d MA $2.79

P/E (TTM) -28.3x

EV/EBITDA 19.1x

P/B —

Debt/Equity -1.8x

ROE 7.5%

P/FCF -59.6x

RSI (14) —

ATR (14) —

Beta 1.17

50d MA $2.56

200d MA $2.79

Avg Volume 5.6M

About

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterole…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 10, 2026	AMC	0.23	0.22	-4.3%	2.70	-0.7%	-4.1%	-8.5%	-9.6%	-0.4%	+0.4%	—
Nov 6, 2025	AMC	-0.09	-0.16	-77.8%	2.50	+0.0%	+6.4%	+15.2%	+24.0%	+21.2%	+18.4%	—
Aug 5, 2025	AMC	-0.17	-0.02	+88.2%	1.62	+0.6%	+18.5%	+11.7%	+15.4%	+14.2%	+10.5%	—
May 6, 2025	AMC	-0.18	-0.21	-16.7%	0.98	+1.5%	-10.7%	-8.5%	-18.2%	-18.1%	-20.0%	—
Mar 4, 2025	AMC	-0.14	-0.10	+28.6%	1.77	+0.6%	-6.8%	-10.2%	-4.5%	-10.7%	-12.4%	—
Nov 7, 2024	AMC	-0.14	-0.15	-7.1%	2.11	-0.9%	+8.1%	+19.4%	+15.2%	+5.7%	-0.5%	—
Aug 12, 2024	AMC	-0.15	-0.05	+66.7%	1.84	+1.1%	-2.2%	+1.1%	+7.1%	+6.5%	+3.3%	—
May 7, 2024	AMC	0.05	0.34	+580.0%	2.37	-4.2%	-13.9%	-11.8%	-7.6%	-5.9%	-8.0%	—
Feb 27, 2024	AMC	-0.53	-0.50	+5.7%	2.90	+0.7%	-11.4%	-13.4%	-12.1%	-15.9%	-17.2%	—
Nov 7, 2023	AMC	-0.42	-0.37	+11.9%	1.03	+1.9%	-3.8%	-14.2%	-12.1%	-8.2%	+5.8%	—
Aug 1, 2023	AMC	-0.63	-0.46	+27.0%	1.69	-3.6%	+5.9%	-3.0%	-3.6%	-5.9%	-4.1%	—
May 9, 2023	AMC	-0.65	-0.79	-21.5%	1.42	+1.4%	+2.8%	+4.9%	+8.5%	+19.7%	+19.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 13	Citizens	Maintains	Market Outperform → Market Outperform	—	$2.47	$2.56	+3.6%	-1.2%	+8.9%	+9.7%	+1.6%	+5.3%
Mar 3	Needham	Maintains	Buy → Buy	—	$3.27	$3.12	-4.6%	-11.0%	-11.0%	-15.3%	-16.8%	-7.0%
Sep 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.75	$2.83	+2.9%	-3.3%	-8.7%	-9.8%	-11.6%	-6.9%
Jun 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.17	$1.15	-1.7%	-6.8%	-6.0%	-8.5%	-11.1%	-8.5%
May 7	Needham	Maintains	Buy → Buy	—	$0.98	$0.99	+1.5%	-10.7%	-8.5%	-18.2%	-18.1%	-20.0%
Apr 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.88	$0.89	+1.0%	+4.4%	+3.0%	+8.9%	+13.4%	+11.7%
Apr 25	Needham	Maintains	Buy → Buy	—	$0.88	$0.89	+1.0%	+4.4%	+3.0%	+8.9%	+13.4%	+11.7%
Apr 17	Goldman Sachs	Maintains	Neutral → Neutral	—	$0.96	$0.97	+0.6%	-1.4%	-11.6%	-3.5%	-1.5%	-8.6%
Apr 8	Needham	Maintains	Buy → Buy	—	$1.20	$1.24	+3.3%	-11.7%	-12.5%	-20.0%	-15.0%	-16.7%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.67	$1.62	-3.0%	-3.0%	+1.2%	+4.2%	+0.6%	-2.4%
Mar 5	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$1.77	$1.78	+0.6%	-6.8%	-10.2%	-4.5%	-10.7%	-12.4%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.58	$1.65	+4.4%	+12.0%	+4.4%	+0.6%	+7.0%	+0.0%
Feb 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.86	$1.83	-1.6%	-3.8%	+1.1%	+0.5%	+0.0%	+0.5%
Feb 11	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$1.86	$1.83	-1.6%	-3.8%	+1.1%	+0.5%	+0.0%	+0.5%
Jan 23	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$2.20	$2.20	+0.0%	-5.5%	-4.5%	-9.5%	-11.4%	-14.1%
Jan 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.20	$2.20	+0.0%	-5.5%	-4.5%	-9.5%	-11.4%	-14.1%
Jan 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.15	$2.16	+0.5%	+2.3%	-3.3%	-2.3%	-7.4%	-9.3%
Jan 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.17	$2.17	+0.0%	+7.8%	+5.1%	+3.2%	+1.8%	+4.1%
Dec 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.55	$2.18	-14.5%	-11.8%	-8.6%	-3.5%	-15.3%	-14.9%
Dec 13	Needham	Maintains	Buy → Buy	—	$2.55	$2.18	-14.5%	-11.8%	-8.6%	-3.5%	-15.3%	-14.9%
Dec 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.69	$2.72	+1.1%	-5.2%	-16.4%	-13.4%	-8.6%	-19.7%
Dec 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.10	$3.05	-1.6%	+4.8%	+18.1%	+7.7%	+12.3%	+23.5%
Dec 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.80	$2.78	-0.7%	+10.7%	+16.1%	+30.7%	+19.3%	+24.3%
Nov 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.57	$2.59	+0.8%	-1.2%	+8.9%	+20.6%	+26.5%	+42.4%
Nov 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.15	$2.13	-0.9%	+12.1%	+12.1%	+14.9%	+17.2%	+19.5%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.11	$2.09	-0.9%	+8.1%	+19.4%	+15.2%	+5.7%	-0.5%
Oct 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.61	$1.61	+0.0%	+13.0%	+21.7%	+34.2%	+26.7%	+28.6%
Aug 13	Needham	Maintains	Buy → Buy	—	$1.84	$1.86	+1.1%	-2.2%	+1.1%	+7.1%	+6.5%	+3.3%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.02	$1.86	-7.9%	-8.9%	-10.9%	-7.9%	-2.5%	-3.0%
Jun 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.31	$2.49	+7.8%	-3.9%	+1.3%	+1.3%	+2.2%	+6.1%
Jun 28	Needham	Maintains	Buy → Buy	—	$2.31	$2.49	+7.8%	-3.9%	+1.3%	+1.3%	+2.2%	+6.1%
Jun 20	BofA Securities	Downgrade	Neutral → Underperform	—	$2.72	$2.58	-5.1%	-15.8%	-18.8%	-19.9%	-23.2%	-19.9%
May 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.41	$2.44	+1.2%	-1.2%	-6.6%	-11.6%	-12.9%	-10.0%
May 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.48	$2.48	+0.0%	-2.8%	-4.0%	-9.3%	-14.1%	-15.3%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.37	$2.27	-4.2%	-13.9%	-11.8%	-7.6%	-5.9%	-8.0%
May 7	Needham	Maintains	Buy → Buy	—	$2.12	$2.38	+12.3%	+11.8%	-3.8%	-1.4%	+3.3%	+5.2%
Apr 10	Needham	Maintains	Buy → Buy	—	$2.79	$2.72	-2.5%	-9.7%	-17.2%	-23.3%	-30.5%	-31.5%
Mar 25	Needham	Maintains	Buy → Buy	—	$2.29	$2.73	+19.2%	+14.4%	+17.9%	+14.4%	+17.0%	+21.8%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.29	$2.73	+19.2%	+14.4%	+17.9%	+14.4%	+17.0%	+21.8%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.90	$2.92	+0.7%	-11.4%	-13.4%	-12.1%	-15.9%	-17.2%
Feb 27	Needham	Maintains	Buy → Buy	—	$2.63	$2.64	+0.4%	+10.3%	-2.3%	-4.6%	-3.0%	-7.2%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.91	$0.90	-0.6%	+4.5%	+20.4%	+27.0%	+22.6%	+31.5%
Nov 7	Needham	Maintains	Buy → Buy	—	$0.96	$1.06	+10.9%	+7.7%	+3.7%	-7.5%	-5.3%	-1.1%
Oct 2	Needham	Maintains	Buy → Buy	—	$0.98	$1.00	+2.0%	-1.0%	-1.3%	-7.5%	-2.0%	+1.0%
Aug 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.38	$1.47	+6.5%	+14.5%	+18.1%	+15.9%	+15.9%	+13.0%
Aug 2	Needham	Maintains	Buy → Buy	—	$1.69	$1.63	-3.6%	+5.9%	-3.0%	-3.6%	-5.9%	-4.1%
Jun 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.33	$1.40	+5.3%	+2.3%	+3.8%	+3.8%	+0.8%	+4.5%
Jun 15	BofA Securities	Upgrade	Underperform → Buy	—	$1.23	$1.39	+13.0%	+11.4%	+15.4%	+24.4%	+15.4%	+17.9%
Jun 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.36	$1.32	-2.9%	-2.2%	+0.0%	-0.7%	+0.7%	+0.0%
May 9	Needham	Maintains	Buy → Buy	—	$1.35	$1.40	+3.7%	+5.2%	+8.1%	+10.4%	+14.1%	+25.9%

Recent Filings

8-K

Esperion Therapeutics, Inc. -- 8-K Filing

Esperion Therapeutics shareholders will receive contingent payments up to $100 per share in cash upon achieving specified milestones under a merger agreement, providing potential upside beyond the fixed merger consideration.

May 1

8-K · 2.01 !!! Very High

Unknown — 8-K 2.01: Acquisition Completed

Esperion Therapeutics spent $180 million on an acquisition, which dilutes shareholder value and raises questions about integration success and ROI that could pressure the stock near-term.

Apr 2

8-K

Unknown — 8-K Filing

Esperion's explosive 144% revenue growth and strategic acquisition of Corstasis to expand its cardiovascular pipeline demonstrates strong execution, justifying continued investor confidence in the company's growth trajectory.

Mar 10

8-K · 1.01 !!! Very High

Esperion Therapeutics, Inc. -- 8-K 1.01: Merger Agreement

Esperion Therapeutics agreed to merge with Corstasis Therapeutics, combining the two cardiovascular drug developers and potentially expanding Esperion's pipeline and market presence.

Mar 3

Data updated apr 25, 2026 7:44am · Source: massive.com